MAIA
HOLD / NEUTRALMeanRevComposite
38.60
Technical
35.00
Fundamental
39.80
Rank
—
Price
1.34
Hurst
0.19
As of
Sep 16, 2026
Daily
MAIA Biotechnology, Inc.
HealthcareBiotechnologyMAIA Biotechnology is an early-stage drug developer focused on creating precision immunotherapy treatments for various cancer types. The company's primary candidate is Ateganosine, an experimental agent designed to target telomeres and is being tested in patients with non-small cell lung cancer. Founded in 2018 and based in Chicago, Illinois, the firm operates through subsidiary entities.
Market cap
$67.9M
P/E (trailing)
—
P/E (forward)
0.99
PEG ratio
—
Dividend yield
0.00%
Beta
0.28
52w range
0.87 – 3.19
Return on equity
-218.68%
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 1.10 (-11.3%) · range 0.87–2.95
Cycle position
19/ 100 cycle scoreENTRY ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 68 · GOOD SETUP · exit proximity 0
Conviction
40/ 100 · maturity 0%
Buildup.334
EMA entry setup.4268
Fundamentals.2540
Volume profile
POC
1.37
Price vs POC
-19.4%
Overhead supply
99%
Runway
+17.7%
Value area 1.27–1.48 · 99% of 120d volume overhead · heavy supply
Get an AI analyst's read on this ticker.Open the AI analyst
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -9.60% | -2.40% | mature |
| 40d | -8.00% | -2.40% | 21/40d |